Portable Mesh Nebulizer (OEM / Private Label)

Mesh Nebulizer Technology vs Jet and Ultrasonic

Three nebulizer technologies are available for OEM respiratory product development. Understanding the trade-offs determines which is right for your product category.

Jet (compressor-driven). Air flows through a nozzle, creating a venturi effect that atomizes liquid medication. Durable, inexpensive to manufacture, and compatible with virtually all medications — including viscous suspensions. Drawbacks: noise (~55 dB(A)), bulky compressor, slow treatment time (10–15 minutes for a standard 2.5mL fill). Still dominates in hospital and clinic settings where portability is not required.

Ultrasonic. A piezo transducer vibrates at 1–3 MHz, creating surface waves that eject droplets. Quieter than jet, no air compressor required. Two significant limitations: the vibration generates heat, which can degrade temperature-sensitive medications (certain corticosteroids, protein biologics); and particle size is difficult to control — MMAD typically 6–10 µm, which deposits primarily in the upper airway rather than reaching bronchi and alveoli.

Vibrating mesh (piezoelectric membrane). A perforated titanium or stainless steel membrane vibrates at 100–200 kHz, pushing medication through precisely sized apertures. The aerosol is cold (no heat degradation), particle size is controlled by aperture diameter (3–5 µm achieves lower airway deposition), and the device is compact and quiet. This is now the standard technology for portable OEM respiratory devices.

Key sourcing variable: mesh quality. Mesh aperture diameter and titanium purity are the primary quality differentiators between factory tiers. A well-manufactured mesh from a Tier 1 supplier delivers consistent MMAD across the 2000+ session rated life. Budget meshes clog or drift in aperture size after 200–300 sessions, leading to reduced nebulization rate and increased residual volume. ISO 27427 defines the standardized test methods for particle size (cascade impactor measurement), nebulization rate, and residual volume — use these as the acceptance criteria for incoming sample evaluation.

CE Marking and Quality System Requirements

Under EU MDR 2017/745, vibrating mesh nebulizers are Class IIa medical devices (Rule 9 — active therapeutic devices intended for diagnosis, monitoring, treatment, or alleviation of disease). CE marking under MDR requires:

ISO 13485 certification at the factory. The quality management system scope must specifically cover the device type (nebulizers/respiratory devices). Ask for the current certificate with the notified body name and certificate number — verify on the EUDAMED database. Certificates expire and must be renewed annually; an expired ISO 13485 certificate invalidates the CE marking.

Technical documentation per MDR Annex II. This includes a clinical evaluation report referencing ISO 27427 performance data, risk management documentation per ISO 14971, and post-market surveillance plans. A credible factory will provide the technical documentation index for review before you commit to MOQ. If a factory cannot provide this, they are selling a CE-labeled product without a valid CE marking — a significant legal liability for importers.

EU Notified Body conformity assessment. Unlike self-declaration (permitted for Class I devices), Class IIa requires a notified body to review the quality management system and technical documentation. The NB certificate number appears on the CE declaration of conformity.

For the UK market post-Brexit, UKCA marking is required on a separate timeline. For the US market, 510(k) clearance from the FDA is required — most Chinese OEM factories do not hold their own US clearance and will provide technical documentation to support a buyer-filed submission.

Medication Compatibility and Mesh Maintenance

Mesh compatibility across medication types is an important pre-qualification step that many OEM buyers skip.

Suspension medications. Budesonide inhalation suspension (a commonly prescribed corticosteroid) is a particle suspension, not a solution. Mesh apertures must be sized appropriately to allow suspension particles to pass without clogging. Ask the factory for nebulization efficiency data for budesonide suspension specifically — a well-designed mesh should deliver >70% of the nominal dose within the respirable fraction (<5 µm MMAD). Factories without this data have likely not characterized their mesh with suspension medications.

Self-cleaning vibration. After each treatment session, the mesh should execute a cleaning vibration cycle at higher amplitude than the nebulization mode — this clears residual medication before it dries in the apertures. Verify this feature is implemented and that the cleaning amplitude is genuinely higher (not just re-running the nebulization cycle). Dried medication residue is the primary cause of premature mesh failure in field use.

Medication cup material compliance. The cup must be made from BPA-free polypropylene meeting EU Directive 10/2011 (plastics in contact with food and pharmaceutical substances) or USP Class VI (for US market). Confirm the cup material certificate from the plastic resin supplier — not a factory self-declaration. The cup design should also allow thorough cleaning between medications to prevent cross-contamination; dishwasher-safe ratings (up to 60°C) are standard for OEM products targeting the home care segment.

Internal link: see our wearable and health device sourcing expertise for related product categories, and our factory audit service for quality system verification before committing to medical device production orders. The factory audit checklist covers ISO 13485 QMS verification steps specific to medical device factories.